XML 25 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:    
Net loss $ (107,254,126) $ (135,117,352)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 1,752,147 2,621,649
Amortization of intangible assets 0 145,417
Amortization of operating lease right-of-use assets 1,377,895 736,472
Change in fair value of common stock warrant liability (2,808,608) 0
Impairment of goodwill 0 10,513,371
Impairment of intangible assets 0 1,984,444
Deferred taxes 0 (32,046)
Non-cash stock-based compensation 6,595,108 11,072,486
Non-cash interest on senior convertible notes (355,654) 155,814
Amortization of discounts on investments (1,690,527) (4,686,144)
Realized loss on sales of short-term investments 1,905,369 4,805,804
Net (gain) loss on disposal of fixed assets (22,466) 317,997
Loss (gain) on equity investment in affiliated entity 1,166,443 (773,145)
Net unrealized gain on available-for-sale equity securities (2,077,182) (5,850,626)
Changes in operating assets and liabilities:    
Accounts receivable, including from affiliated entities 1,206,172 9,332,988
Prepaid expenses and other current assets, including from affiliated entities 1,483,393 39,020,611
Other assets 38,900 78,729
Accounts payable and accrued expenses, including due to affiliated entities (3,367,087) (45,989,061)
Accrued clinical trial expenses (343,522) (8,228,691)
Operating lease right-of-use assets and liabilities, net (1,573,401) (2,020,971)
Grant funding liability, including from affiliated entity (109,407) (2,453,297)
Net cash used in operating activities (104,076,553) (124,365,551)
Cash flows from investing activities:    
Purchases of investments (54,138,026) (203,475,052)
Proceeds from sale or maturity of investments 158,637,578 284,932,562
Purchases of capital assets (487,832) (320,898)
Proceeds from sale of capital assets 59,319 6,219,263
Net cash provided by investing activities 104,071,039 87,355,875
Cash flows from financing activities:    
Repayment of convertible senior notes (16,415,000) 0
Proceeds from issuance of pre-funded warrants, net of issuance costs 16,146,397 0
Proceeds from issuance of common stock, net of issuance costs 36,033,473 5,461,745
Proceeds from issuance of warrants 16,063,796 0
Proceeds from stock option exercises 67,675 0
Taxes paid related to net share settlement of equity awards (420,795) (466,646)
Net cash provided by financing activities 51,475,546 4,995,099
Effect of exchange rate changes on cash and cash equivalents 32,403 (3,920)
Increase (decrease) in cash and cash equivalents 51,502,435 (32,018,497)
Cash and cash equivalents, beginning of period 14,310,862 46,329,359
Cash and cash equivalents, end of period 65,813,297 14,310,862
Supplemental disclosure:    
Interest paid 533,487 1,066,975
Issuance of common stock as part of litigation settlement $ 0 $ 14,000,000